Bausch + Lomb stock reports 9.1 percent revenue growth

Published on 09/24/2026 at 20:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bausch + Lomb stock posted adjusted EPS of USD 0.15 in Q2 2026, matching consensus. Full-year revenue guidance stands at USD 5.44 billion to USD 5.54 billion.

Bausch + Lomb stock, healthcare, medical devices, Q2 2026 results, NYSE, Illustration mit AI erstellt.

Bausch + Lomb Corporation (ISIN CA0717051076) was trading at USD 16.90 on the NYSE on September 24, 2026 at 2:49 p.m. ET, down 0.88 percent; its Q2 2026 revenue reached USD 1.394 billion, up 9.1 percent year over year. The result keeps the company on a growth track while the share price remains 10.63 percent below its 52-week high of USD 18.91.

Revenue beats the quarterly estimate

Bausch + Lomb reported Q2 2026 revenue of USD 1.394 billion, compared with a Wall Street estimate of USD 1.37 billion, according to Investing.com. The USD 24 million beat represented a 1.7 percent advantage over the estimate and gives the revenue trend more weight than the modest intraday decline.

Adjusted EPS came in at USD 0.15 in Q2 2026, matching consensus, while adjusted EBITDA rose to USD 246 million and the margin reached 17.6 percent, the same report said. The combination of revenue growth and stable adjusted earnings points to operating leverage that investors can track in the next report.

Guidance and eye care pipeline

For full-year 2026, Bausch + Lomb expects revenue of USD 5.44 billion to USD 5.54 billion, compared with a FactSet estimate of USD 5.47 billion, according to MarketScreener. That guidance range places the midpoint at USD 5.49 billion, USD 20 million above the cited estimate.

The company also added a product milestone on September 11, 2026, when European CE Mark approval was announced for the SeeLyra femtosecond laser, according to Business Wire. The approval expands the surgical portfolio and adds a dated commercial development alongside the Q2 financial figures.

Stock trades below yearly high

Bausch + Lomb stock stood at USD 16.90 on the NYSE on September 24, 2026 at 2:49 p.m. ET, with a market capitalization of USD 6,036,092,640. The 52-week range was USD 13.77 to USD 18.91, placing the current quote USD 3.13 above the low and USD 2.01 below the high.